Is It Too Late to Buy Iovance Biotherapeutics Stock? [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
Iovance stock would go on to reach share price highs of more than $18. Today, however, the stock trades at less than half that price. And in just three months, it has fallen by more than 40% as the hype surrounding the business appears to have evaporated. Is it too late to invest in Iovance, or could the best be yet to come for this promising healthcare company The stock peaked after it obtained accelerated approval for Amtagvi On Feb. 16, the Food and Drug Administration (FDA) granted accelerated approval for Iovance's cell therapy treatment, Amtagvi (lifileucel), to treat advanced melanoma. It marked the first time regulators approved a one-time individualized T-cell therapy for treating a solid tumor cancer. The following day, the stock would jump by more than 31% and within two weeks reach its 52-week high of $18.33. It's not uncommon for a biotech stock to soar on such a positive development, as it gives investors hope for the company's long-term prospects for generating
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.MarketBeat
- Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced MelanomaGlobeNewswire
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at JMP Securities from $25.00 to $23.00. They now have a "market outperform" rating on the stock.MarketBeat
IOVA
Earnings
- 5/9/24 - Beat
IOVA
Sec Filings
- 6/28/24 - Form 8-K
- 6/13/24 - Form 4
- 6/13/24 - Form 4
- IOVA's page on the SEC website